Adcetris is the first drug approved for the Hodgkin's lymphoma since 1977. The FDA sped approval up under an accelerated, six month system reserved for therapies that show promising results in ...

ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in the European Union (EU) in ...

ADCETRIS, an antibody-drug conjugate, targets CD30-positive tumor cells and has been used to treat over 55,000 patients in the U.S. since its first approval in 2011.

Adcetris was recently approved by the FDA in 2011, so it’s fairly new, but Kathleen, a local cancer survivor who relapsed three times, said the drug has been a miracle for her.

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized by the European Commission on June 3, 2025, for newly diagnosed adult ...

Adcetris is an antibody-drug conjugate (ADC) that is designed to be stable in the bloodstream but to release monomethyl auristatin E (MMAE) upon internalization into CD30-expressing tumor cells.

Seagen Inc. today announced that 12- and 24- month progression free survival data will be presented for an ADCETRIS ® and immunotherapy combination in early and advanced stage classical Hodgkin ...

Adcetris is available as a 50mg/vial lyophilized powder for intravenous (IV) infusion in single-use vials. For more information call (855) 473-2436 or visit Adcetris.com.

The combination of Adcetris, Revlimid and Rituxan significantly increased overall survival compared with Revlimid/Rituxan alone in patients with relapsed/refractory diffuse large B-cell lymphoma ...

Approval of Adcetris as a first line of treatment for patients with advanced lymphoma could push sales past $1 billion in the U.S. Seattle Genetics Inc. is a step closer to winning Food and Drug ...

NICE calculated that Adcetris will likely cost below £30,000 per Quality Adjusted Life Year, its upper threshold in normal situations, and is therefore a cost-effective use of NHS resources.

Adcetris’ net product revenue in the first quarter of 2013 was $33.9 million. Adcetris is also being evaluated in other indications. Seattle Genetics carries a Zacks Rank #2 (Buy).